Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (188)	1/18/2004 3:26:07 PM
From: tuck	Read Replies (1) \| Respond to of 255

Well, the only documents I can find that seem to relate to this predate Novo's start of the PIII trial. Could be that guidelines were not yet issued for aqueous aerosol delivery systems, while guidelines for the dry powder formulations were. But again, I can't find guidelines for 2003. Only July '02, and the trial started in September of that year. fda.gov google.fda.gov Perhaps someone at Novo's investor relations could help with this. Cheers, Tuck